Genprex (NASDAQ:GNPX) Announces Quarterly Earnings Results

Genprex (NASDAQ:GNPX) posted its quarterly earnings results on Monday. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.56, Zacks reports.

Genprex Trading Up 3.3%

Shares of Genprex stock opened at $0.29 on Tuesday. Genprex has a fifty-two week low of $0.22 and a fifty-two week high of $4.09. The stock has a 50 day moving average of $0.30 and a 200 day moving average of $0.72.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.